Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2014 1
2015 3
2016 3
2017 4
2018 6
2019 5
2020 4
2021 4
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
[Good Controlled Chylothorax in Gastric Carcinoma].
Tsuji H, Hara S, Urano J, Samukawa T, Makio T, Sugiyama Y, Hosoi K, Ogiyama H, Murayama Y, Min KY. Tsuji H, et al. Among authors: sugiyama y. Gan To Kagaku Ryoho. 2018 Oct;45(10):1449-1451. Gan To Kagaku Ryoho. 2018. PMID: 30382043 Review. Japanese.
Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: A retrospective multidisciplinary study.
Tasaki Y, Sugiyama Y, Hamamoto S, Naiki T, Uemura T, Yokota K, Kawakita D, Nakamura M, Ogawa R, Shimura T, Mimura Y, Hotta Y, Odagiri K, Ito N, Iida M, Kimura Y, Komatsu H, Kataoka H, Takiguchi S, Morita A, Iwasaki S, Okuda K, Niimi A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: sugiyama y. Cancer Med. 2023 Dec;12(24):21666-21679. doi: 10.1002/cam4.6724. Epub 2023 Nov 21. Cancer Med. 2023. PMID: 37986680 Free PMC article.
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma.
Iida K, Naiki T, Etani T, Nagai T, Sugiyama Y, Isobe T, Aoki M, Nozaki S, Noda Y, Shimizu N, Tomiyama N, Gonda M, Kamiya H, Kubota H, Nakane A, Ando R, Kawai N, Yasui T. Iida K, et al. Among authors: sugiyama y. Sci Rep. 2024 Jan 30;14(1):2520. doi: 10.1038/s41598-024-53158-1. Sci Rep. 2024. PMID: 38291115 Free PMC article.
Elevated eosinophils proportion as predictor of immune-related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma.
Tasaki Y, Hamamoto S, Sugiyama Y, Tomiyama N, Naiki T, Etani T, Taguchi K, Matsuyama N, Sue Y, Mimura Y, Kubota H, Noda Y, Aoki M, Moritoki Y, Nozaki S, Kurokawa S, Okada A, Kawai N, Yasui T, Kimura K. Tasaki Y, et al. Among authors: sugiyama y. Int J Urol. 2023 Oct;30(10):866-874. doi: 10.1111/iju.15220. Epub 2023 Jun 6. Int J Urol. 2023. PMID: 37278575
42 results